# GPT-5.4 (R1) Review

**Role:** External referee review
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-25T16:48:26.130822
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 13886 in / 5522 out
**Response SHA256:** 9b31fc4131574773

---

This paper asks an important and policy-relevant question: do “safe country of origin” (SCO) designations change adjudication or primarily deter applications? The paper’s central empirical claim is striking: after absorbing origin-year, destination-year, and origin-destination fixed effects, SCO designations have essentially no effect on first-instance recognition rates, while applications fall. The distinction between adjudication-stage and application-stage effects is potentially valuable, and the institutional setting is interesting.

That said, in its current form I do not think the paper is publication-ready for a top general-interest journal or AEJ:EP. The core concerns are not mainly presentational; they are about identification, treatment timing, inferential validity, and the paper’s calibration of its main claims. The adjudication result may yet be true, but the current design does not establish it cleanly enough, and the deterrence and “system-wide” claims are substantially less secure than the paper’s rhetoric suggests.

## 1. Identification and empirical design

### A. Main triple-difference design: promising but not yet fully credible

The baseline specification in Section 4,
\[
Y_{cjt}=\beta SCO_{cjt}+\gamma_{cj}+\delta_{ct}+\theta_{jt}+\varepsilon_{cjt},
\]
is a sensible starting point. Pair fixed effects absorb time-invariant corridor heterogeneity; origin×year effects absorb common origin shocks; destination×year effects absorb common destination shocks. If treatment timing is as-good-as-random conditional on these fixed effects, the design is attractive.

But the paper does not yet make the identifying assumption sufficiently credible for the stated causal claim.

The key issue is **policy endogeneity at the origin-destination level**. Governments may designate specific origins as safe in response to changing composition or perceived merit of that origin’s caseload in that destination. Your FE structure removes common origin-year and destination-year shocks, but it does **not** remove shocks specific to a given origin-destination pair, such as:

- bilateral migration-network changes,
- route-specific redirection,
- corridor-specific changes in legal aid, screening, or administration,
- destination-specific political salience of a given origin group.

Those are exactly the kinds of shocks plausibly correlated with designation timing.

The paper acknowledges policy endogeneity in Section 4.2, but the empirical response is not yet strong enough.

### B. The event study does not adequately test the identifying assumption

The event study in Section 5.1 / Figure 1 is not persuasive as currently implemented. You restrict to treated pairs and omit origin×year FE “to preserve event-time variation.” But that omission is consequential: once origin×year FE are removed, pre-trends may simply reflect common origin shocks or cohort composition, not pair-specific anticipation or treatment endogeneity.

In other words, the event study is not a clean diagnostic for the identifying assumption underlying the main specification. In fact, your own discussion of positive pre-trends at \(t-4\) and \(t-3\) suggests substantial nonparallel dynamics around designation. The claim that “the clean immediate pre-period” at \(t-2\) suffices is not convincing, especially with annual data and late-in-year treatment adoption.

For a paper whose headline is “designation has no causal effect on recognition rates,” pre-trend evidence needs to be much more rigorous:
- estimator compatible with staggered timing,
- event-time coefficients defined relative to not-yet-treated / never-treated controls,
- specification as close as possible to the main identifying equation,
- transparent cohort support.

### C. Treatment timing is not coherent enough with annual data

This is a major concern.

Several key designation events occur in **late calendar year** (e.g., Germany November 2014, October 2015; Austria October 2014; Germany September 2023 excluded, appropriately). Yet treatment is coded at the **year** level. With annual outcomes, coding an entire year as treated when the policy starts in October or November creates severe timing misclassification.

This matters in two ways:

1. **Recognition-rate outcome**: first-instance decisions in year \(t\) are often decisions on applications filed earlier. A designation introduced in October 2015 is unlikely to affect most decisions recorded in calendar year 2015. More broadly, decisions are a stock variable with processing lags, while the treatment is a flow policy. Contemporaneous annual decisions are therefore a poor measure of immediate adjudication response.

2. **Applications outcome**: applications may respond more quickly, but even here late-year adoption means the annual treatment indicator averages mostly pre-treatment months with a few post-treatment months.

This timing problem is not a minor attenuation issue; it goes directly to whether the null on adjudication reflects no effect or simply measurement against the wrong outcome window. The paper needs a much more serious treatment-timing discussion and redesign. At minimum:
- code treatment using fractional exposure within year,
- drop adoption years or treat them as partial-treatment years,
- estimate distributed lags/leads,
- and explain expected timing separately for applications vs decisions.

### D. Decision outcomes are not aligned with the mechanism

Relatedly, the paper’s adjudication claim is stronger than the design supports because first-instance decisions at year \(t\) do not correspond to the same applicant pool as first-time applications at year \(t\). If SCO designations affect who applies, then the effect on recognition rates may show up only with lag, after the post-treatment applicant composition reaches the decision stage.

This is fundamental. A contemporaneous null on decision rates does **not** imply no adjudication effect unless processing lags are short and stable, or unless you explicitly model dynamic effects over decision cohorts. The paper needs to confront this directly.

### E. Composition of the comparison group is questionable

You use 9 designated-origin nationalities and 10 never-designated “conflict-origin” controls (Section 3). That is a very asymmetric control set. The control origins are structurally different from the treated origins in baseline asylum merits, conflict intensity, and geopolitical dynamics. The fixed effects help, but the identifying variation still relies on treated-origin timing relative to this control structure. The paper should show much more that results are not an artifact of using very high-recognition, never-designated origin groups as anchors.

At minimum, I would want:
- results on a treated-origins-only sample using not-yet-treated origins as controls where possible,
- matched-control origins with closer pre-treatment levels/trends,
- and sensitivity to excluding the high-conflict control origins.

### F. Sample-selection issues from the ≥10-decision threshold

The sample is restricted to cells with at least 10 decisions (Section 3). Because the paper’s own mechanism is deterrence, treatment may reduce later decisions enough to push cells below the threshold. That can induce endogenous sample selection in the recognition-rate regressions. You mention this concern in Section 4.2, but no actual evidence is shown in the paper. For publication, this must be demonstrated, not asserted.

You should report:
- treatment effects on cell inclusion,
- robustness to no threshold / alternative thresholds,
- and ideally a specification using counts of positive and total decisions rather than rates on a selected support.

## 2. Inference and statistical validity

### A. Main inference is not yet adequate given few treated clusters

You cluster at the destination-country level with 22 clusters (Section 4.1). However, treatment is concentrated in **seven designating destinations** (Section 3). The effective number of treated clusters is therefore small. In such settings, conventional cluster-robust inference can be misleading even if the total number of clusters is above 20.

The paper’s “pairs cluster bootstrap” is not enough as described. What is needed is inference suited to **few treated clusters / policy-level clustering**, e.g.:
- wild cluster bootstrap at the destination level,
- permutation/randomization procedures that respect the clustered adoption process,
- and explicit discussion of leverage from the treated destinations.

Your current RI permutes treatment timing “within years” among treated pairs (Section 4.2; Appendix). That does not obviously preserve the policy assignment structure, since designation typically happens at the destination-origin legislative level, not independently across pair-years. The placebo procedure should mirror the actual adoption process more closely.

### B. The Callaway–Sant’Anna result is a major contradiction, not a minor sensitivity check

This is the single most important empirical issue in the paper.

In Section 5.5 / Table 5, the heterogeneity-robust staggered DiD estimate is
\[
ATT=-0.049 \quad (SE=0.017),
\]
which is economically meaningful and statistically significant. That is not a trivial discrepancy from the main estimate of \(-0.004\). It is a qualitatively different conclusion.

The paper currently downplays this by citing small cohorts, dropped observations, and long post-windows. That is not sufficient. For a modern applied micro paper, if the estimator designed precisely to address staggered-adoption heterogeneity yields a significant negative effect, the burden is on the author to reconcile the estimands and show why the preferred estimator is more credible.

At present, the paper’s headline “no causal effect on recognition rates” is too strong given this unresolved contradiction.

You need to do at least the following:
- decompose the TWFE/triple-diff weighting problem;
- show cohort-specific and event-time effects under a heterogeneity-robust estimator;
- clarify how always-treated and pre-sample treated units enter;
- show results excluding early-treated cohorts;
- show not-yet-treated-only comparisons where possible;
- explain whether the CS design and the main design are estimating the same causal object.

Until then, the null result is not secure.

### C. Statistical power claims are overstated

The abstract and text emphasize a “precisely estimated zero” and MDE of 7 pp. But the paper’s own alternative estimator finds about 5 pp, significant. That alone undermines the rhetorical force of the power argument.

Also, a 7 pp MDE is not obviously small in this context. Relative to recognition rates for some designated origins, 5–7 pp could be substantively important. So the claim that the paper rules out meaningful effects should be softened.

### D. Application regressions are not strongly estimated

The own-designation effect on log applications is \(-0.428\) with SE \(0.249\), \(p=0.10\) (Table 3). That is suggestive, not decisive. Yet the abstract says designations “reduce applications by approximately 35%” as if firmly established. That overstates the strength of evidence.

Moreover, for count outcomes like applications, log(applications + 1) is not obviously the best choice. A PPML specification on counts with fixed effects would be more natural and robust to zeros and heteroskedasticity.

### E. Denominator issues in rate regressions

Recognition rate is positive decisions divided by total decisions, and specifications are estimated unweighted or weighted by total decisions. That is acceptable as a descriptive approach, but for causal inference it would be useful to model the count structure more directly:
- positive decisions with total decisions as exposure,
- binomial/quasi-binomial or PPML-like approaches,
- and robustness to weighting choices.

Given substantial variation in cell size (Table 1), linear regressions on rates may be sensitive to noise in small cells despite the ≥10 threshold.

## 3. Robustness and alternative explanations

### A. Alternative explanations for the null remain unresolved

A null contemporaneous effect on recognition rates could reflect:
1. true absence of adjudication effect;
2. mistimed treatment coding;
3. decision-lag mismatch;
4. heterogeneous effects averaging out;
5. attenuation from coarse binary treatment;
6. endogenous sample selection from thresholding.

The current paper discusses several of these verbally, but does not empirically separate them.

### B. Mechanism claims exceed the evidence

The paper repeatedly claims the effect operates through “selection into the asylum system rather than decisions within it.” This is plausible, but the evidence is indirect. You do not observe applicant-level characteristics, application merits, or case composition. A fall in applications plus a null on contemporaneous decision rates is **consistent with** selection, but it is not direct evidence that composition changed.

Likewise, the “protection-type substitution” result is very weak:
- Geneva coefficient 0.045, \(p=0.10\)
- subsidiary/humanitarian \(-0.080\), \(p=0.08\)

These are borderline estimates, with different sample sizes across columns, and should not be treated as more than suggestive.

### C. The “system-wide deterrence” claim is not identified

The paper itself notes the key problem: in Table 3, column 2, the regressor varies at the origin×year level, and you omit origin×year FE. That means the estimate is driven exactly by variation most likely confounded by changing origin conditions. This specification cannot support the strong claim that deterrence is “system-wide” rather than diversionary.

For publication in a top journal, this result should either be:
- substantially redesigned with more credible identification, or
- reframed as descriptive/speculative and moved out of the headline contribution.

### D. Missing robustness on lags and treatment windows

Given the institutional timing, the paper needs:
- lagged effects on decisions (1-year, 2-year, possibly 3-year),
- treatment-year exclusion,
- partial-year coding,
- separate effects for early vs late adopters,
- and perhaps stacked event studies around adoption.

Without these, the central null is too fragile.

## 4. Contribution and literature positioning

The paper has a potentially interesting conceptual contribution: distinguishing policy effects on entry into an administrative system from effects on adjudication inside that system. That is a good angle.

However, the literature positioning is incomplete on the methods side and somewhat overstated on the substantive side.

### A. Methods literature that should be engaged more directly

Given staggered adoption and heavy FE structure, the paper should engage:
- Sun and Abraham (2021) on event studies with heterogeneous treatment effects,
- de Chaisemartin and D’Haultfœuille (2020, 2022) on TWFE with staggered adoption,
- Goodman-Bacon (2021) on DiD decomposition,
- MacKinnon and Webb / Ferman and Pinto on few treated clusters and inference.

These are not optional citations here; they are central to the paper’s identification and inference choices.

### B. Substantive literature claims should be toned down

The statement that “No prior study has asked whether a specific asylum policy instrument operates by altering bureaucratic decisions or by selecting who faces those decisions” is likely too strong. Even if few papers estimate both margins causally in this setting, the conceptual distinction is not novel enough to warrant that level of exclusivity. I would revise the contribution claim to “provides new evidence” rather than “first causal estimates” unless the authors perform a much more exhaustive literature demonstration.

### C. Bureaucracy/discretion literature is under-integrated

The discussion invokes Lipsky, but the paper would benefit from stronger engagement with empirical work on administrative discretion and rule implementation, particularly work showing formal rules may bind unevenly across agencies. That would help frame the plausible interpretation that SCO is a noisy or weakly implemented treatment rather than inert policy.

## 5. Results interpretation and claim calibration

This is where the paper most needs restraint.

### A. The adjudication headline is overstated

The abstract says “The designation has no causal effect on recognition rates.” That is too categorical given:
- significant CS estimate of about -5 pp,
- imperfect timing,
- decision-flow mismatch,
- few treated clusters,
- and unresolved heterogeneity.

A more appropriate claim would be: “In the authors’ preferred annual triple-difference specification, SCO designations are not associated with robust changes in contemporaneous first-instance recognition rates.”

That is less punchy, but more defensible.

### B. The deterrence claim is stronger than the evidence

A 35% application decline with \(p=0.10\) should not be presented as settled fact, especially in the abstract. It is suggestive evidence of deterrence, not conclusive evidence.

### C. The system-wide interpretation should be substantially softened

Given the admitted origin-year confounding, the statement that deterrence “operates system-wide” goes well beyond what the design supports. At most, the current evidence is descriptive and consistent with a system-wide pattern.

### D. Policy implications are too broad relative to evidence

The paper draws strong implications for the 2025 EU common list, including that harmonization “will not improve decision consistency” and may “amplify system-wide deterrence.” Those implications are premature because:
- the adjudication null is not yet secure,
- the system-wide channel is not causally identified,
- and the common list may differ from national lists in implementation and signaling.

The policy discussion should be scaled back accordingly.

## 6. Actionable revision requests

### 1. Must-fix issues before acceptance

#### 1. Resolve treatment timing and decision-lag mismatch
- **Issue:** Annual coding of late-year designations and use of contemporaneous decisions likely mismeasure exposure.
- **Why it matters:** This could mechanically produce attenuation or misleading null effects on adjudication.
- **Concrete fix:** Recode treatment using partial-year exposure or drop adoption years; estimate distributed lags for decisions; separately justify expected timing for applications and decisions; if possible, move to quarterly/monthly data or at least show timing robustness.

#### 2. Reconcile the main triple-diff estimate with the significant Callaway–Sant’Anna estimate
- **Issue:** Preferred estimate is near zero, but heterogeneity-robust DiD gives a significant negative effect.
- **Why it matters:** This contradiction directly undermines the headline conclusion.
- **Concrete fix:** Provide decomposition of estimands/weights; cohort-specific ATT/event-study results; exclude early cohorts; compare never-treated vs not-yet-treated controls; explain sample differences transparently.

#### 3. Strengthen inference for few treated clusters
- **Issue:** Treatment is concentrated in seven designating destinations; standard clustered inference may be unreliable.
- **Why it matters:** Statistical validity is a non-negotiable condition for publication.
- **Concrete fix:** Use wild cluster bootstrap or other few-treated-cluster methods; redesign permutation inference to respect clustered legislative adoption; report treated-cluster leverage diagnostics.

#### 4. Redesign or greatly soften the system-wide deterrence analysis
- **Issue:** Column (2) in Table 3 is confounded by origin×year shocks because origin×year FE are omitted.
- **Why it matters:** The current design cannot support a causal claim of system-wide deterrence.
- **Concrete fix:** Either develop a credible strategy for that parameter or reframe it explicitly as descriptive suggestive evidence and remove it from the abstract/headline contribution.

#### 5. Address endogenous sample selection from the ≥10-decision threshold
- **Issue:** Treatment may affect whether cells enter the estimation sample.
- **Why it matters:** Selection on observability can bias rate regressions.
- **Concrete fix:** Show treatment effects on sample inclusion; report robustness to alternative/no threshold; consider count-based specifications on the fuller sample.

### 2. High-value improvements

#### 6. Implement modern staggered-adoption event-study estimators
- **Issue:** Current event study omits origin×year FE and is not well aligned with the main design.
- **Why it matters:** Pre-trend evidence is central to credibility.
- **Concrete fix:** Use Sun-Abraham or related estimators; present cohort support and not-yet-treated comparisons; show dynamic effects with treatment-year dropped.

#### 7. Re-estimate applications using count models
- **Issue:** Log(applications + 1) is ad hoc for sparse counts and heteroskedasticity.
- **Why it matters:** The deterrence margin is one of the paper’s main contributions.
- **Concrete fix:** Estimate PPML with the same FE structure; show robustness to alternative transformations and extensive-margin outcomes.

#### 8. Probe heterogeneity more systematically
- **Issue:** Average effects may mask substantial heterogeneity across countries/cohorts.
- **Why it matters:** Heterogeneity could explain the TWFE/CS discrepancy and change interpretation.
- **Concrete fix:** Report cohort-specific and destination-specific treatment effects; examine major adopters separately (Germany, Austria, Belgium, France).

#### 9. Clarify the role of always-treated and pre-sample-treated units
- **Issue:** Several countries/origins are treated before 2008.
- **Why it matters:** These units affect identification, CS estimation, and interpretation.
- **Concrete fix:** Explicitly describe how pre-sample treatment contributes to each estimator; show results excluding always-treated units.

### 3. Optional polish

#### 10. Calibrate contribution and abstract claims more conservatively
- **Issue:** Current rhetoric outruns evidence.
- **Why it matters:** Overclaiming weakens credibility.
- **Concrete fix:** Soften “no causal effect,” “system-wide deterrence,” and “first causal estimates” unless stronger evidence is added.

#### 11. Expand methods citations
- **Issue:** Key staggered-DiD and few-cluster papers are missing.
- **Why it matters:** This is essential for situating the empirical design.
- **Concrete fix:** Add Sun & Abraham (2021), Goodman-Bacon (2021), de Chaisemartin & D’Haultfœuille (2020/2022), and relevant few-cluster inference references.

## 7. Overall assessment

### Key strengths
- Important, policy-relevant question.
- Interesting conceptual distinction between application-stage and adjudication-stage effects.
- Rich cross-country policy variation.
- Good instinct to go beyond raw recognition-rate comparisons.
- Commendable effort to discuss endogeneity and provide robustness checks.

### Critical weaknesses
- Treatment timing is too coarse relative to policy adoption and outcome measurement.
- The adjudication outcome is not well aligned with the mechanism because of case-processing lags.
- Main null result is contradicted by a significant heterogeneity-robust staggered-DiD estimate.
- Inference is not yet persuasive given few treated clusters.
- The “system-wide deterrence” claim is not credibly identified.
- Several headline conclusions are too categorical for the evidence presented.

### Publishability after revision
I think there is a potentially publishable paper here, but not in its current form. The core idea is strong enough to merit serious revision. However, the paper needs more than incremental robustness checks; it needs a redesign of timing, dynamic treatment analysis, and inferential strategy, and a more disciplined interpretation of what the data can and cannot show.

DECISION: REJECT AND RESUBMIT